摘要
目的：观察重组人血小板生成素（rhTPO）对白血病化疗后重度血小板减少症（≤20×109/L）的疗效和安全性。方法：选15例急性白血病经化疗达完全缓解（CR）后巩固化疗中患者作为治疗组。化疗前血小板计数均≥100×109/L。化疗前1天即开始给予皮下注射rhTPO15000IU,每天一次至骨髓抑制期后血小板恢复。选20例急性白血病巩固化疗中未予rhTPO预防治疗作为对照组。结果：白血病患者化疗后出现重度血小板减少症的时间推迟至化疗后12天,持续时间减少至4~5天,恢复时间提前6天,减少了血小板输注的次数,且仅有不影响治疗的轻微不良反应。结论：rhTPO应用于白血病化疗后重度血小板减少安全而有效。
Objective： To explore the effect of recombinant human thrombopoietin（rhTPO） on leukemia after chemotherapy of severe thrombocytopenia（ 20 x 109 / L） of the efficacy and safety of.Methods： 15 cases of acute leukemia after chemotherapy achieved complete remission（CR） after consolidation chemotherapy in patients as treatment group.Chemotherapy before platelet counts were 100 x 109 / L.1 days before chemotherapy was given subcutaneous injection of rhTPO15000IU,once a day to platelet recovery after myelosuppressive phase.20 cases of acute leukemia consolidation chemotherapy in prevention of treatment as the control group without rhTPO.Results： Leukemia after chemotherapy in patients with severe thrombocytopenia in a time delayed until 12 days after chemotherapy,duration reduced to 4 ~ 5 days 6 days ahead of time,recovery time,reducing the number of platelet transfusions,and only does not affect the treatment of minor adverse reactions.Conclusion： The application of rhTPO in patients with leukemia after chemotherapy of severe thrombocytopenia is safe and effective.
出处
《中国医药导刊》
2012年第4期585-586,共2页
Chinese Journal of Medicinal Guide
关键词
重组人血小板生成素
白血病化疗
重度血小板减少
Recombinant human thrombopoietin（rhTPO）
Leukemia chemotherapy
Severe thrombocytopenia
